The short version of regulatory status fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-04 and is reviewed periodically as new material appears.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
The four substrates of this enzyme are 1-deoxy-11-oxopentalenic acid, reduced nicotinamide adenine dinucleotide phosphate (NADPH), oxygen, and a proton. It products are neopentalenolactone D, oxidised NADP+, and water. The starting ketone is made as part of a biosynthetic pathway in Streptomyces avermitilis which leads to pentalenolactone and related compounds. The enzyme is a Baeyer-Villiger monooxygenase that uses flavin adenine dinucleotide as a cofactor.
According to Bucknell, while the "branched version" refers directly to the six sense objects, the "looped version" and the standard version instead use the term nama-rupa as "a collective term for the six types of sense object." He cites various passages from the early sources and the scholarship of Yinshun, Reat and Watsuji in support. Bucknell thinks that name and form was eventually misinterpreted as referring to "mind and body", causing discrepancies in the 12 fold series and making it possible to interpret the beginning of the chain as referring to rebirth. According to Bucknell, the linear list, with its distortions and changed meaning for consciousness and name and form, may have developed when the list came to be recited in reverse order. Bucknell further notes that the "branched version", corresponds with the interpretation of the twelve nidanas as mental processes while the "looped version", (which sees consciousness as the "rebirth consciousness") corresponds with the "three lives" interpretation.
The Michel I Government was the Federal Government of Belgium formed following the 2014 Belgian government formation and sworn in on 11 October 2014. The administration was a centre-right coalition of the New Flemish Alliance (N-VA), the Christian Democratic and Flemish (CD&V), the Open Flemish Liberals and Democrats (Open Vld) and the Reformist Movement (MR). The prime minister was Charles Michel. The government had an agenda of socio-economic reforms, especially through austerity measures, with its priorities being improving Belgium's economic competitiveness and reducing unemployment. It fell in December 2018 over the Global Compact for Migration. It was followed by the Michel II Government as a centre minority coalition cabinet of Christian Democratic and Flemish (CD&V), the Open Flemish Liberals and Democrats (Open Vld) and the Reformist Movement (MR). On 26 October 2019, it was announced that Sophie Wilmès would take over the role of prime minister from Michel on 1 November 2019, and form a new government as the first ever female prime minister of Belgium.
== Reception == GameSpy named Garry's Mod the "PC Mod of the Year" in 2005. Craig Pearson of GamesRadar regarded it one of the best mods for cooperative gameplay in 2007. In 2017, Brendan Caldwell of Rock Paper Shotgun described the game as a "must-own sandbox game", while PCGamesN included it in its 2019 list of the "best sandbox games on PC".
Sources: en.wikipedia.org
The Salmonella Mutagenesis test (Ames test) uses multiple strains of Salmonella typhimurium that are auxotrophic to histidine to test whether a given chemical can cause mutations by observing its auxotrophic property in response to an added chemical compound. The mutation a chemical substance or compound causes is measured by applying it to the bacteria on a plate containing histidine then moving the bacteria to a new plate without sufficient histidine for continual growth. If the substance does not mutate the genome of the bacteria from auxotrophic to histidine back to prototrophic to histidine, then the bacteria would not show growth on the new plate. So by comparing the ratio of the bacteria on the new plate to the old plate and the same ratio for the control group, it is possible to quantify how mutagenic a substance is, or rather, how likely it is to cause mutations in DNA. A chemical is considered positive for Ames test if it causes mutations increasing the observed reversion rate and negative if presents similar to the control group. There is a normal, but small, number of revertant colonies expected when an auxotrophic bacteria is plated on a media without the metabolite it needs because it could mutate back to prototrophy. The chances of this are low and therefore cause very small colonies to be formed. If a mutagenic substance is added, however, the number of revertants would be visibly higher than without the mutagenic substance.
== Further reading == Krönig, A. (1856), "Grundzüge einer Theorie der Gase", Annalen der Physik, 001 (10): 315–22, Bibcode:1856AnP...175..315K, doi:10.1002/andp.18561751008. Facsimile at the Bibliothèque nationale de France (pp. 315–22). Clausius, R. (1857), "Ueber die Art der Bewegung, welche wir Wärme nennen", Annalen der Physik und Chemie, 176 (3): 353–79, Bibcode:1857AnP...176..353C, doi:10.1002/andp.18571760302. Facsimile at the Bibliothèque nationale de France (pp. 353–79). Joseph Louis Gay-Lussac – Liste de ses communications, archived from the original on October 23, 2005 . (in French)
=== Chemical reactions === CO2 is a potent electrophile having an electrophilic reactivity that is comparable to benzaldehyde or strongly electrophilic α,β-unsaturated carbonyl compounds. However, unlike electrophiles of similar reactivity, the reactions of nucleophiles with CO2 are thermodynamically less favored and are often found to be highly reversible. The reversible reaction of carbon dioxide with amines to make carbamates is used in CO2 scrubbers and has been suggested as a possible starting point for carbon capture and storage by amine gas treating. Only very strong nucleophiles, like the carbanions provided by Grignard reagents and organolithium compounds react with CO2 to give carboxylates:
Approaches to data analysis that provide a posterior probability distribution for some parameter (e.g. treatment effect), derived from the observed data and a prior probability distribution for the parameter. The posterior distribution is then used as the basis for statistical inference. (ICH E9) Best practice
== Taxonomy == The genus Glycine may be divided into two subgenera, Glycine and Soja. The subgenus Soja includes the cultivated soybean, G.max, and the wild soybean, treated either as a separate species G.soja, or as the subspecies G.max subsp. soja. The cultivated and wild soybeans are annuals. The wild soybean is native to China, Japan, Korea and Russia. The subgenus Glycine consists of at least 25 wild perennial species: for example, G. canescens and G. tomentella, both found in Australia and Papua New Guinea. Perennial soybean (Neonotonia wightii) belongs to a different genus. It originated in Africa and is now a widespread pasture crop in the tropics. Like some other crops of long domestication, the relationship of the modern soybean to wild-growing species can no longer be traced with any degree of certainty. It is a cultigen with a very large number of cultivars.
Sources: en.wikipedia.org
Typically, a wide-local excision is performed, in which the tumor is excised including a safety-margin of healthy tissue to ensure its entire removal, which is confirmed by a pathologist. In more advanced disease, a (partial) vulvectomy may need to be performed in order to remove some or all of the vulva. Advanced-stage melanomas can be treated with checkpoint inhibitors.
== Transitional charter == The 1991 conference ultimately resulted in the adoption of the "Transitional Period Charter of Ethiopia" and the official establishment of a transitional government. Much to the relief of the international community, the conference attendees agreed on major transformations of the country's political and economic systems that would usher in liberal institutions that were purportedly intended to guarantee fair representation, encourage plurality, and demand transparency at the executive level. This and other key initiatives of the TGE were outlined in the Transitional Period Charter of Ethiopia, which was divided into five parts:
==== Mate choice ==== Mate choice is seen in cuttlefish species, where females prefer some males over others, though characteristics of the preferred males are unknown. A hypothesis states that females reject males by olfactory cues rather than visual cues. Several cephalopod species are polyandrous – accepting and storing multiple male spermatophores, which has been identified by DNA fingerprinting. Females are no longer receptive to mating attempts when holding their eggs in their arms. Females can store sperm in two places (1) the buccal cavity where recently mated males place their spermatophores, and (2) the internal sperm-storage receptacles where sperm packages from previous males are stored. Spermatophore storage results in sperm competition; which states that the female controls which mate fertilizes the eggs. In order to reduce this sort of competition, males develop agonistic behaviors like mate guarding and flushing. The Hapalochlaena lunulata, or the blue-ringed octopus, readily mates with both males and females.
== Challenges == RNAi intersects with a number of other pathways; as of 2010, it was not surprising that, on occasion, nonspecific effects were triggered by the experimental introduction of an siRNA. When a mammalian cell encounters a double-stranded RNA such as an siRNA, it may mistake it as a viral by-product and mount an immune response. Furthermore, because structurally related microRNAs modulate gene expression largely via incomplete complementarity base pair interactions with a target mRNA, the introduction of an siRNA may cause unintended off-targeting. Chemical modifications of siRNA may alter the thermodynamic properties that also result in a loss of single nucleotide specificity. Because siRNA drugs are oligonucleotides rather than small molecules, they are not substrates for cytochrome P450 enzymes and do not induce or inhibit CYP-mediated metabolism at clinically relevant concentrations. Drug–drug interaction (DDI) assessment therefore focuses on endocytic transporter pathways, off-target mRNA silencing, and in cases where the silenced target gene encodes a regulator of drug metabolism secondary effects on CYP or transporter expression.
== Effects == Baikiain is hypothesized to be the causative agent of illnesses resulting from consumption of food products containing tara flour. In several cases documented in 2022 people became ill after consuming meals containing tara flour with high concentrations of Baikian (3% dry weight). People experienced acute gastrointestinal and liver disease with clinical signs of hepatotoxicity. Baikiain was found not to harm mammalian or human cells in culture but did cause liver injury and depletion of glutathione in rodent models.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.